This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wasan, K. M.
Right arrow Articles by Rossignol, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wasan, K. M.
Right arrow Articles by Rossignol, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 2796-2803, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2796-2803.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Kishor M. Wasan,1* Olena Sivak,1 Richard A. Cote,1 Aaron I. MacInnes,1 Kathy D. Boulanger,1 Melvyn Lynn,2 William J. Christ,3,{dagger} Lynn D. Hawkins,3 and Daniel P. Rossignol2

Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada,1 Eisai Medical Research Inc., Teaneck, New Jersey 07666,2 Eisai Research Institute, Andover, Massachusetts 018103

Received 26 August 2002/ Returned for modification 30 December 2002/ Accepted 3 June 2003

The objective of this study was to determine the distribution profile of the novel endotoxin antagonist E5564 in plasma obtained from fasted human subjects with various lipid concentrations. Radiolabeled E5564 at 1 µM was incubated in fasted plasma from seven human subjects with various total cholesterol (TC) and triglyceride (TG) concentrations for 0.5 to 6 h at 37°C. Following these incubations, plasma samples were separated into their lipoprotein and lipoprotein-deficient fractions by ultracentrifugation and were assayed for E5564 radioactivity. TC, TG, and protein concentrations in each fraction were determined by enzymatic assays. Lipoprotein surface charge within control and phosphatidylinositol-treated plasma and E5564’s influence on cholesteryl ester transfer protein (CETP) transfer activity were also determined. We observed that the majority of E5564 was recovered in the high-density lipoprotein (HDL) fraction. We further observed that incubation in plasma with increased levels of TG-rich lipoprotein (TRL) lipid (TC and TG) concentrations resulted in a significant increase in the percentage of E5564 recovered in the TRL fraction. In further experiments, E5564 was preincubated in human TRL. Then, these mixtures were incubated in hypolipidemic human plasma for 0.5 and 6 h at 37°C. Preincubation of E5564 in purified TRL prior to incubation in human plasma resulted in a significant decrease in the percentage of drug recovered in the HDL fraction and an increase in the percentage of drug recovered in the TRL and low-density lipoprotein fractions. These findings suggest that the majority of the drug binds to HDLs. Preincubation of E5564 in TRL prior to incubation in normolipidemic plasma significantly decreased the percentage of drug recovered in the HDL fraction. Modifications to the lipoprotein negative charge did not alter the E5564 concentration in the HDL fraction. In addition, E5564 does not influence CETP-mediated transfer activity. Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles.

* Corresponding author. Mailing address: Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall Ave., Vancouver, BC V6T 1Z3, Canada. Phone: (604) 822-4889. Fax: (604) 822-3035. E-mail: Kwasan{at}interchange.ubc.ca.

{dagger} Present address: Department of Membrane Transport, Harvard Medical School, Andover, MA 01810.

Antimicrobial Agents and Chemotherapy, September 2003, p. 2796-2803, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2796-2803.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rossignol, D. P., Wasan, K. M., Choo, E., Yau, E., Wong, N., Rose, J., Moran, J., Lynn, M. (2004). Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers. Antimicrob. Agents Chemother. 48: 3233-3240 [Abstract] [Full Text]  
  • Lynn, M., Wong, Y. N., Wheeler, J. L., Kao, R. J., Perdomo, C. A., Noveck, R., Vargas, R., D'Angelo, T., Gotzkowsky, S., McMahon, F. G., Wasan, K. M., Rossignol, D. P. (2004). Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia. J. Pharmacol. Exp. Ther. 308: 175-181 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»